An appeal by gaming giant Aristocrat Technologies of an IP Australia ruling revoking four of its patents will head to trial in September ahead of outcomes in two high stakes cases over the patentability of computer software.
Patents at the centre of a high stakes IP dispute between tech giants Motorola and Hytera have significantly more than the necessary āscintilla of inventivenessā to be deemed valid, Motorola said on the first day of a month-long trial.
Printer giant Seiko Epson has won its cross-appeal against cartridge reseller Calidad in a Full Federal Court decision that further clarifies the extent to which patentees can prevent those acquiring a patent’s title from repurposing or manipulating the original product.
Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.
The potential source of alleged “industrial espionageā in Motorolaās case against Hytera over the intellectual property for its digital radio mobile devices has been revealed as a mystery woman with two laptops that contained a āvery large number of Motorola documentsā, a court has heard.
The Copyright Tribunal erred by including rights in a reissued Foxtel licence agreement that fell outside the authority of the licence grant holder, the Phonographic Performance Company of Australia, the Full Federal Court has found.
Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.
Motorola has slammed Hytera for engaging in āindustrial espionage on a grand scaleā, after more than a thousand Motorola-branded documents were found in the possession of the Chinese radio maker.
A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.
German pharmaceutical company Boehringer has struck back at a patent lawsuit brought by Teva, filing a cross-claim alleging Teva is threatening to infringe three of its patents related to its blockbuster inhaler Spiriva with the planned launch of a competing inhaler in Australia.